Axonics® to Report Third Quarter 2021 Financial Results on November 4

Rhea-AI Summary

Axonics, Inc. (NASDAQ: AXNX) will release its third quarter 2021 financial results on November 4, 2021, after market close. Following the release, the company will conduct a conference call at 4:30 p.m. ET, accessible via phone and a live webcast. Axonics specializes in developing products for bladder and bowel dysfunction, including its rechargeable sacral neuromodulation system and Bulkamid^® for urinary incontinence. The company serves a significant market with overactive bladder affecting an estimated 87 million adults in the U.S. and Europe.

Positive

• Strong market presence with products offered in hundreds of medical centers.
• Established reimbursement coverage in the U.S. and most European countries.

Negative

• None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021.

In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 8798817.

A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived on the Axonics website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for patients with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005165/en/

Neil Bhalodkar

Investor Relations

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When will Axonics report its third quarter 2021 financial results?

Axonics will report its third quarter 2021 financial results after market close on November 4, 2021.

What time is the Axonics conference call scheduled?

The conference call is scheduled for 4:30 p.m. Eastern Time on November 4, 2021.

How can I access the Axonics conference call?

The conference call can be accessed by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 8798817.

What products does Axonics develop for bladder and bowel dysfunction?

Axonics develops a rechargeable sacral neuromodulation system and Bulkamid^® for patients with overactive bladder and urinary incontinence.

How many adults are affected by overactive bladder in the U.S. and Europe?

An estimated 87 million adults in the U.S. and Europe suffer from overactive bladder.